PHASE III PLACEBO-CONTROLLED TRIAL TO EVALUATE DEXAMETHASONE USE FOR EVEROLIMUS INDUCED ORAL STOMATITIS: PREVENTION VERSUS EARLY TREATMENT APPROACHES Save

Date Added
March 19th, 2019
PRO Number
Pro00087480
Researcher
Antonio Giordano

List of Studies

Silhouette
Keywords
Cancer/Breast
Summary

This study is for subjects who have been diagnosed with cancer and will be receiving a drug called everolimus as part of your usual care. The purpose of this study is to see if treating patients with dexamethasone mouthwash at the start of cancer treatment will lower the chance of getting painful mouth sores.

Institution
MUSC
Recruitment Contact
Nancy McGaha
(864) 725-5105
nmcgaha@selfregional.org

A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer Save

Date Added
March 4th, 2019
PRO Number
Pro00086652
Researcher
Frank Brescia

List of Studies


Profiles_link
Keywords
Cancer, Cancer/Breast
Summary

This study is for patients who are 70 years old or over and have been recently diagnosed with estrogen receptor positive, HER2 negative metastatic breast cancer. The purpose of this study is to find out the side effects that the standard, FDA-approved combination treatment of letrozole or fulvestrant and palbociclib has on patients 70 years old and over.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, Then in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor-positive Advanced Breast Cancer Save

Date Added
January 22nd, 2019
PRO Number
Pro00084301
Researcher
Antonio Giordano

List of Studies

Silhouette
Keywords
Cancer/Breast, Drug Studies, Women's Health
Summary

This is an open-label, nonrandomized, dose escalation and dose expansion, safety, efficacy, PK and PD evaluation study of SAR439859 administered orally as monotherapy, then in combination with palbociclib. The study will last approximately 26 months, and participation in the study may last 4 to 8 weeks or longer. The length of participation in this study will depend on how well subjects tolerate the study drug and the condition of their disease.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Stress Reactivity among African American Breast Cancer Survivors Save

Date Added
October 19th, 2018
PRO Number
Pro00060958
Researcher
Chanita Hughes-halbert

List of Studies


Profiles_link
Keywords
Cancer/Breast, Inflammation, Minorities
Summary

Outcomes following a breast cancer diagnosis are different by race and ethnicity with African American women having poorer survival compared to Caucasian women. Research has shown that differences in personal health factors can contribute to breast cancer outcomes and explain racial differences. This study will examine how personal-level factors relating to biological, psychological, and physiological issues play a role in outcomes among African American breast cancer survivors.

Institution
MUSC
Recruitment Contact
Melanie Jefferson
843-876-2430
sweatma@musc.edu

Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502 Save

Date Added
October 18th, 2018
PRO Number
Pro00082693
Researcher
Frank Brescia

List of Studies


Profiles_link
Keywords
Cancer/Breast
Summary

This study is for patients with breast cancer who have enrolled or are planning to enroll to the Alliance study A011502, "Aspirin for Breast Cancer Study" (or ABC study).

Institution
MUSC
Recruitment Contact
Nancy McGaha
(864) 725-5105
nmcgaha@selfregional.org

Breast Cancer Survivors' Unmet Needs After Completion of Radiation Treatment Save

Date Added
June 11th, 2018
PRO Number
Pro00068596
Researcher
Michelle Pembroke

List of Studies

Keywords
Cancer/Breast
Summary

Many breast cancer patients experience emotional, physical, psychological and financial issues after treatment ends. Very few studies have explored the unmet needs of breast cancer patients after the completion of radiation treatment. The patient reported findings from this qualitative study will guide a survivorship education program designed to better meet the needs of breast cancer patients.

Institution
MUSC
Recruitment Contact
Michelle Pembroke
904-588-1459
brennami@musc.edu

PHASE III RANDOMIZED TRIAL OF HYPOFRACTIONATED POST MASTECTOMY RADIATION WITH BREAST RECONSTRUCTION Save

Date Added
March 20th, 2018
PRO Number
Pro00076282
Researcher
Jennifer Harper

List of Studies


Profiles_link
Keywords
Cancer/Breast
Summary

This study is for patients who have been diagnosed with stage 2 or stage 3 breast cancer and their doctor has recommended that they receive radiation therapy after mastectomy to prevent your breast cancer from coming back. The purpose of this study is to determine whether a short-course radiation therapy option (3 to 4 weeks) after mastectomy is as safe and effective in the setting of breast reconstruction as the usual 5 to 6 week treatment course.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

PROSPECTIVE EVALUATION OF CARVEDILOL IN PREVENTION OF CARDIAC TOXICITY IN PATIENTS WITH METASTATIC HER-2+ BREAST CANCER, PHASE III Save

Date Added
March 1st, 2018
PRO Number
Pro00073765
Researcher
Frank Brescia

List of Studies


Profiles_link
Keywords
Cancer/Breast
Summary

This study is for patients with metastatic breast cancer who are receiving therapy that may cause heart problems. The purpose of this study is to test whether carvedilol can reduce the occurrence of heart problems during their cancer treatment.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Tomosynthesis Mammographic Imaging Screening Trial (TMIST) Save

Date Added
December 21st, 2017
PRO Number
Pro00073365
Researcher
Dag Pavic

List of Studies


Profiles_link
Keywords
Cancer/Breast
Summary

This study is for women being screened for breast cancer. The main purpose of this study is to determine whether screening for breast cancer with tomosynthesis mammography is superior to digital mammography for breast cancer screening.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A "Window Trial" On Boswellia, An Extract From Frankincense, For Breast Cancer Primary Tumors Save

Date Added
June 20th, 2017
PRO Number
Pro00067127
Researcher
Nancy Demore

List of Studies

Silhouette
Keywords
Cancer/Breast
Summary

The overall goal of this study is to see if taking BosPure (boswellia serrata) will change the make up of the tumors of patients who have breast cancer. BosPure is a supplement made from the boswellia serrata plant, which helps to reduce inflammation in the body. BosPure is not approved by the United State Food and Drug Administration (FDA) for the treatment of your disease.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-cto-clinops@musc.edu

Change_preferences

-- OR --

Create_login